Coloplast revenue and financials

COLO.B · Nasdaq Copenhagen · DKK

kr 418.80+2.15%+kr 8.80

Close · October 6, 2026

In the fiscal year ended September 2024, Coloplast reported revenue of kr 27.03B (+10.33% year over year). Net income was kr 5.05B, a net margin of 18.7%.

Annual revenue · 2024: kr 27.03B

kr 22.58B2022
kr 24.5B2023
kr 27.03B2024

Fiscal year ending in September. Sources and method on the page Methodology and sources.

At a glance

Revenue growth: +10.33%; FY to Sep 2024 vs FY to Sep 2023
Net income growth: +5.62%; FY to Sep 2024 vs FY to Sep 2023
Net margin: 18.7%; FY to Sep 2023: 19.5%

Financial data

Amounts in millions of DKK; per-share values in DKK; shares in millions.

Income statement · Annual
Item	FY to Sep 2024	FY to Sep 2023	FY to Sep 2022
Total revenue	27,030	24,500	22,579
Cost of revenue	8,761	8,172	7,050
Gross profit	18,269	16,328	15,529
Selling, general and administrative	10,069	8,633	7,802
Research and development	913	872	866
Operating income	7,286	6,845	6,910
EBIT	7,190	6,663	6,299
EBITDA	8,480	7,732	7,229
Interest expense	795	638	172
Pre-tax income	6,395	6,025	6,127
Income tax	1,343	1,242	1,421
Net income	5,052	4,783	4,706
Net income to common shareholders	5,052	4,783	4,706
Basic EPS	22.46	22.21	22.14
Diluted EPS	22.46	22.20	22.11
Average shares (basic)	225	215	213
Average shares (diluted)	225	216	213